Last reviewed · How we verify
Sofetabart Mipitecan
Sofetabart Mipitecan is a folic acid antagonist that inhibits thymidylate synthase.
Sofetabart Mipitecan is a folic acid antagonist that inhibits thymidylate synthase. Used for Metastatic colorectal cancer.
At a glance
| Generic name | Sofetabart Mipitecan |
|---|---|
| Also known as | LY4170156 |
| Sponsor | Eli Lilly and Company |
| Drug class | Folic acid antagonist |
| Target | Thymidylate synthase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By inhibiting thymidylate synthase, Sofetabart Mipitecan disrupts DNA synthesis and repair, leading to cell death in rapidly dividing cancer cells. This mechanism is particularly effective in tumors with high levels of thymidylate synthase expression.
Approved indications
- Metastatic colorectal cancer
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Fatigue
- Anemia
Key clinical trials
- A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer (PHASE3)
- A Study of LY4170156 in Participants With Selected Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sofetabart Mipitecan CI brief — competitive landscape report
- Sofetabart Mipitecan updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI